According to a recent study by Future Market Insights (FMI), the global biopsy device market is projected to experience steady, moderate growth over the coming decade. Valued at approximately USD 2,274.1 million in 2024, the market is expected to expand at a CAGR of 3.7% from 2024 to 2034, reaching an anticipated valuation of USD 3,270.4 million by the end of the forecast period.
As healthcare systems worldwide continue to invest in early diagnostic tools, demand for biopsy devices is on an upward trajectory, with the market expected to grow 1.4 times its current size over the next ten years. Key factors driving this growth include advances in minimally invasive biopsy techniques, rising incidence of cancer and other chronic diseases requiring diagnostic biopsies, and technological innovations aimed at improving patient outcomes and diagnostic accuracy.
Future Market Insights’ analysis suggests that this positive yet moderate growth trend will be supported by strategic investments in research and development within the biopsy device ecosystem, especially those focused on enhancing precision and patient comfort. This report provides critical insights for stakeholders aiming to leverage upcoming opportunities in the biopsy device market and emphasizes the sector's readiness to support the evolving demands of healthcare providers and patients alike.
Opportunities for Growth:
As healthcare providers increasingly prioritize early detection and preventive healthcare, opportunities for growth within the biopsy device market are abundant. Medical tourism, which has seen a rise in Thailand due to its cost-effective and high-quality medical services, also presents a unique opportunity for market expansion.
Industry Outlook:
The next decade is poised to witness strong collaborations between local healthcare providers and international medical device manufacturers, ensuring that advanced biopsy technologies are more widely available across Thailand. Moreover, the country's aging population and the growing focus on non-communicable diseases will further fuel demand for diagnostic solutions such as biopsy devices.
Market Highlights:
- India: Expected to have the highest growth rate, with a CAGR of 5.8% among all countries.
- France: Leading the European market with a forecasted growth rate of 4.3%.
- Needle Biopsy Market Segment: Projected to secure the largest market share of 36.6% by 2024.
- Medical Diagnosis: The largest application segment, holding 61.3% of the market share by 2024.
Challenges and Recommendations:
Ethical and legal considerations surrounding biopsy procedures present significant challenges. Adherence to strict procedural standards is essential to ensure clean practices and maintain market integrity.
Biopsy Device Trends: Find Out More in Our Comprehensive Report Filled with Key Insights!
Competitive Landscape:
The global biopsy device market is highly competitive, with several key players strengthening their positions through strategic initiatives:
- B. Braun Melsungen AG acquired Intermedt Medizin & Technik GmbH in March 2022, diversifying the Avitum division’s product portfolio.
- Becton, Dickinson, and Company collaborated with GOCC in March 2024 to advance bloodstream infection testing and expand operations in Poland.
Key Companies in the Market:
- CR Bard
- Becton, Dickinson, and Company
- B. Braun Melsungen AG
- Hologic Inc.
- Cook Medical
- Devicor Medical Products Inc.
- Argon Medical Inc.
Market Segmentation:
- By Product Type: Guidance System, Needles, Guns, Reagents and Kits, Others
- By Application: Medical Diagnosis, Scientific Research
- By End Use: Hospital, Specialized Oncology Centres, Diagnostic Centers, Research Institutes
By Region: North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, The Middle East and Africa
